Propiedades antimicrobianas
Mecanismos bactericidas del SGS, microbioma de sanguijuelas, destrucción mediada por complemento y la paradoja de la infección
Research Classification
Last updated: March 14, 2026
The medicinal leech occupies a paradoxical position with respect to infection. On one hand, SGS contains components with documented antimicrobial activity, and the leech's intestinal environment destroys or attenuates many pathogenic organisms. On the other hand, the leech harbors symbiotic bacteria — principally Aeromonas veronii biovar sobria — that may cause wound infection in vulnerable patients. Clinical practice must account for both aspects of this duality. This page examines the evidence for antimicrobial activity of SGS, characterizes the Aeromonas symbiont and its clinical significance, and identifies strategies for minimizing infection risk.
Evidencia experimental histórica
The earliest systematic investigation of microorganism survival in the leech digestive tract was conducted by Andreev (1923), who fed leeches on infected guinea pigs, rats, and chickens and tracked pathogen viability over weeks to months. His findings remain foundational.
| Pathogen | Detection in Leech Intestinal Blood | Outcome |
|---|---|---|
| Bact. typhi abdominalis | Present in first days; barely detectable by day 16 | Killed in intestinal canal |
| Bact. paratyphus | Undetectable at 3 months | Killed in intestinal canal |
| Bact. suiseptici | Visible at day 10; undetectable at day 38 | Killed in intestinal canal |
| Anthrax bacillus | Morphologically indistinct by day 3; absent from smears by day 17; detected by guinea pig inoculation | Attenuated but virulent residue persists |
| Plague bacillus | Blood from 4 leeches injected into healthy guinea pig at day 20; animal became ill with typical plague | Survived in intestinal canal |
| Tuberculosis bacillus | Tested | Variable survival |
| Spirochetes | Tested | Shorter survival than bacteria |
| Trypanosoma brucei & T. equiperdum | Tested | Shorter survival than bacteria |
Andreev demonstrated that SGS extracted from the cephalic region exhibits bactericidal properties against many — but not all — infectious agents. Protozoa survived for shorter periods than bacteria. A critical finding: transmission of pathogens from an infected to a healthy animal is possible only if a leech previously fed on an infected host is applied to a new animal — underscoring the absolute requirement for single-use leeches in clinical practice.
Petrov et al. (1936)
Extract from leech heads inhibited Staphylococcus growth in vitro; at higher concentrations, it killed the organisms. Chamberland-filtered extract retained weaker bactericidal activity, suggesting both protein and non-protein antimicrobial components.
Shpolyansky (1944)
In patients with parametritis, the antimicrobial effect was quantified by measuring staphylococcal colony counts on agar before and after hirudotherapy. Colony numbers decreased 2–3 fold — the first clinical quantification of antimicrobial activity.
Shishkina (1953)
Confirmed that Staphylococcus aureus is killed within the leech intestinal canal within one month.
Bosz & Delezenne (in Blumenthal, 1936)
Dogs infected with lethal doses of streptococci survived when pretreated with leeches; untreated controls died. This dramatic survival experiment suggests systemic immunomodulatory effects beyond local antimicrobial action.
Mecanismos antimicrobianos modernos del SGS
Four distinct antimicrobial mechanisms have been identified in SGS and the leech intestinal environment. Together they form an integrated antimicrobial system that protects both the leech (from pathogen contamination of ingested blood) and, incidentally, the host (from wound infection at the bite site).
1. Destabilase-Lysozyme (Direct Antimicrobial)
A dual-function enzyme (12.3 kDa) with muramidase activity that hydrolyses peptidoglycan in bacterial cell walls. Gram-positive bacteria are most susceptible. The same protein exhibits isopeptidase (thrombolytic) activity — cleaving ε-(γ-Glu)-Lys bonds in stabilized fibrin. This dual function was confirmed by Zavalova et al. (2000): a single molecule provides both antimicrobial defense and fibrinolytic capability.
Destabilase-lysozyme represents the primary direct antimicrobial effector in SGS. Three recombinant isoforms have been produced and characterized, with crystal structure resolved at 1.1 Å (Kurdyumov et al., 2021).
2. Enhancement of Phagocytosis
SGS enhances the phagocytic activity of neutrophils and macrophages at the bite site and within the leech intestinal canal. Leech extracts activate phagocytosis in vitro, suggesting that SGS components serve as opsonins or direct activators of phagocytic cells. This mechanism augments the host's innate immune response rather than replacing it.
3. Complement-Mediated Bactericidal Activity
In the leech intestinal canal, the complement cascade in ingested blood activates and forms the C5b-9 membrane attack complex, which inserts into bacterial cell membranes and causes lysis. This mechanism is effective against E. coli (sharply decreased by 42 hours) but ineffective against Aeromonas species, which have protective S-layer proteins (52 kDa) on their outer membrane (Merino et al., 1996).
4. Complement Modulation (Dual Role)
A complex relationship exists between SGS and complement. SGS can block complement activation via both classical and alternative pathways through the C1s complement inhibitor. This creates an evolutionary paradox: complement kills susceptible pathogens in ingested blood (beneficial), but SGS eventually attenuates complement activity (protecting the symbiotic Aeromonas population). The leech has evolved to permit initial complement-mediated pathogen clearance while preserving its digestive symbiont.
Evidencia antimicrobiana clínica: Estudio de otitis de Seleznev (n=273)
Seleznev et al. (1992) — Three-Arm Comparison
273 patients with acute external otitis, chronic otitis media, and tinnitus were treated with one of three modalities:
| Modality | Sessions | Outcome |
|---|---|---|
| SGS via microelectrophoresis | 1 (single session) | 25–30% less effective than full HT |
| Standard hirudotherapy | 2–9 sessions | Best microbial reduction + microcirculation |
| Conventional pharmacotherapy | Standard course | Reference comparator |
In all cases, a reduction in colony counts of Staphylococcus aureus, Escherichia coli, and Proteus spp. was observed on the skin surface of the external auditory canal, indicating an antimicrobial effect attributable to destabilase-lysozyme. Objective measurements included microbiological analysis and polarographic assessment of tissue partial oxygen tension. The SGS microelectrophoresis result is significant: even a single session of purified SGS delivery produced measurable antimicrobial activity, confirming that the pharmacological activity of SGS is distinct from mechanical blood extraction.
El microbioma de la sanguijuela: simbiosis de Aeromonas
The identification of the leech's intestinal symbiont has undergone significant taxonomic revision. Early studies reported a single species, Pseudomonas hirudinis (Weiler 1949; K.-Büsing 1951), later re-identified as Aeromonas hydrophila (O'Hare, Whitlock et al. 1983). The definitive taxonomic study by Graf (1999) resolved the question.
Graf (1999): Definitive Taxonomic Identification
Analyzing intestinal canal extracts from European and Mediterranean leeches (obtained from established companies in France, Germany, Switzerland, and England) using 10 specific biochemical tests on 13 intestinal canal extracts, Graf demonstrated that the predominant culture is Aeromonas veronii biovar sobria — not A. hydrophila as previously assumed. Confirmed by genetic analysis. The presence of a pure culture in the leech intestinal canal is remarkable, since animal digestive tracts are typically colonized by complex microbial consortia.
Population Dynamics
The primary stimulus for A. veronii biovar sobria proliferation is ingested blood:
- Baseline: 2 × 104 CFU/mL
- 1 hour post-feeding: 2.5 × 105 CFU/mL
- Doubling time: 1.2 hours
- 12-hour plateau: 5 × 106 CFU/mL
- Total at plateau: 8 × 107 CFU/mL
The leech permits unrestricted growth for the first 12 hours until threshold density is reached, after which proliferation is balanced by bacterial removal (possibly through hemocytosis). Proteinase inhibitors (eglins, bdellins) present in the intestinal canal suppress proliferation after 12 hours (de Chalain, 1996).
Symbiont Functions
A. veronii biovar sobria serves essential digestive functions that the leech cannot perform independently:
- Haemolysis: Erythrocyte lysis for nutrient release
- Enzyme synthesis: Amylase, lipases, proteases
- Vitamin production: Essential cofactors (Fields, 1991)
- Bacteriostatic protein: Prevents blood coagulation
- Competitive exclusion: Suppresses other bacteria
The bacterium permanently inhabits the digestive tract; its role is defined by its ability to synthesize the digestive enzymes the leech itself does not produce.
Aeromonas Species in Leech Microbiome
Beyond the predominant A. veronii biovar sobria, additional Aeromonas species identifiable in the leech microbiome include (Graf, 1999):
Mecanismo de destrucción mediada por complemento
The elegant study by Indergand & Graf (2000) elucidated the complement-dependent mechanism underlying differential pathogen survival in the leech intestinal canal.
| Organism | Complement Sensitivity | 42-Hour Result | 162-Hour Result | Mechanism |
|---|---|---|---|---|
| E. coli | Sensitive | Sharply decreased | Partial recovery (complement inactivation) | C5b-9 membrane lysis |
| Aeromonas spp. | Resistant | Unrestricted growth | Plateau at 8 × 107 CFU/mL | S-layer protein (52 kDa) blocks C5b-9 |
| P. aeruginosa | Partially resistant | Suppressed proliferation | Persisted 162h | Partial complement resistance + competition |
| S. aureus | Partially resistant | Suppressed proliferation | Persisted 162h | Gram-positive wall + competition |
Evolutionary Interpretation
Análisis exhaustivo de flora
Eroglu et al. (2001) — 73 Isolates from 16 Specimens
Bacteria were isolated from the body surface, oral cavity (7/16 specimens), and intestinal canal (15/16 specimens). The 73 isolates comprised:
| Organism | Count | % of Total |
|---|---|---|
| A. hydrophila | 25 | 34% |
| Ochrobactrum anthropi | 23 | 32% |
| Non-fermenting GNB | 12 | 16% |
| Acinetobacter lwoffii | 3 | 4% |
| A. sobria | 2 | 3% |
| Other species | 8 | 11% |
Sources of Contamination
Indergand & Graf (2000) identified multiple potential contamination sources:
- Leech body surface: Environmental organisms from storage water
- Anterior sucker cavity: Microflora may be present (SGS itself is sterile)
- Patient skin flora: Normal commensal organisms at application site
- Prior blood meals: Critically important — during feeding, the leech may regurgitate intestinal contents into the wound
Critical Safety Implication
Tasas de infección clínica
Aeromonas species are present in freshwater environments and are pathogenic for humans and fish (Janda & Abbott, 1998). A. hydrophila, A. veronii biovar sobria, and A. caviae cause septicemia, wound infections, and diarrhea in humans.
| Study | Year | Context | Infection Data |
|---|---|---|---|
| Dabb et al. | 1992 | Reconstructive surgery | 2/4 grafts lost to wound infection |
| de Chalain | 1996 | Meta-analysis (37 + 108 cases) | 7–20% wound infection rate |
| Kount | 1994 | Reconstructive surgery | Up to 20% A. veronii infection |
| Mercer et al. | 1987 | Reconstructive surgery | Up to 20% infection rate |
| Tissot-Guerraz et al. | 1987 | Post-mastectomy | ML application reduced A. hydrophila content |
Risk Factors
- Immunocompromised status: Highest risk group (Dickson 1984; Abrutyn 1988; Wells 1993)
- Reconstructive surgery context: Daily application for graft salvage
- Circulatory disorders: Impaired local immune response
- Non-fasted leeches: Higher bacterial load from prior meals
In the majority of disease cases, patients' immunity had been suppressed at baseline or as a result of medical interventions, supporting classification as opportunistic infections (Khomyakova et al.).
Isakhanyan Reassurance (30+ Years)
Isakhanyan (1991) documented over 30 years of clinical practice with the following protocol: skin prepared with non-sterile cotton swab, hands washed with ordinary tap water without soap, non-sterile dressings applied. Despite these minimal aseptic measures, wound suppuration or signs of infection were never observed. This experience suggests that in immunocompetent patients with properly fasted leeches, the infection risk is low and manageable with standard wound care.
Perfil de sensibilidad antibiótica
| Antibiotic Class | Agents | Sensitivity | Notes |
|---|---|---|---|
| Fluoroquinolones | Ciprofloxacin | 100% | Broad coverage; first-line prophylaxis |
| 3rd-gen cephalosporins | Cefotaxime, ceftazidime | 100% | IV option for serious infections |
| Aminoglycosides | Gentamicin | 100% | Parenteral; monitor renal function |
| TMP/SMX | Trimethoprim/sulfamethoxazole | 100% | Oral alternative |
| 1st-gen cephalosporins | Cephalexin, cefazolin | HIGH RESISTANCE | NOT recommended for Aeromonas |
Modern Resistance Concerns
Patogenicidad: datos del modelo murino
Virulence Studies
Laboratory studies demonstrated high pathogenicity of Aeromonas strains isolated from the leech intestine:
- Intraperitoneal injection of 24-hour bacterial culture suspension at doses of 500, 100, 20, and even 4 organisms caused death at various time points with signs of sepsis.
- Addition of antibiotics to leech feed at biofactories increased mean time to death and lowered the LD50, indicating that husbandry practices modulate symbiont virulence.
These data underscore the importance of biofactory quality control: antibiotic management of leech feed can directly reduce the virulence of the bacterial population transmitted during clinical use.
Modelo antimicrobiano integrado: cuatro sistemas
The antimicrobial landscape of hirudotherapy involves the interplay of four distinct systems, each with specific targets and limitations:
| System | Mechanism | Target | Limitation |
|---|---|---|---|
| 1. SGS Direct | Destabilase-lysozyme cell wall hydrolysis + phagocytosis enhancement | Gram-positive bacteria (primary); broad antimicrobial at bite site | Limited against Gram-negative organisms with protective outer membranes |
| 2. Complement | C5b-9 membrane attack complex in ingested blood | Complement-sensitive organisms (E. coli, many pathogens) | Ineffective against Aeromonas (S-layer resistance) |
| 3. SGS Modulation | C1s complement inhibitor blocks classical + alternative pathways | Attenuates complement over time (protects symbiont) | Reduces complement-mediated killing of susceptible pathogens |
| 4. Competitive Exclusion | A. veronii dominance via bacteriostatic proteins + resource competition | Suppresses proliferation of non-symbiotic organisms | Does not eliminate persistent organisms (P. aeruginosa, S. aureus) |
The clinical antimicrobial action of hirudotherapy at the bite site reflects the balance between SGS antimicrobial components (destabilase-lysozyme, phagocytosis enhancement) and the potential for Aeromonas transmission from the intestinal canal. Proper leech preparation, patient selection, and prophylactic antibiotic use shift this balance toward net antimicrobial benefit.
Infection Prevention Strategies
1. Leech Husbandry & Quality Control
- Maintain leeches in clean water free of pathogens with mandatory microbiological monitoring
- Use only blood from healthy, tested animals for biofactory feeding
- Use only fasted leeches (minimum 6 months without feeding)
- Test random samples for intestinal blood presence before clinical use
2. Pre-Treatment Preparation
Mackay et al. (1999) recommended keeping leeches in an antibiotic solution for 12 hours before treatment to reduce intestinal bacterial load. This approach must be balanced against potential effects on leech vitality and SGS quality.
3. Prophylactic Antibiotics
For patients at elevated risk (immunocompromised, post-surgical, reconstructive), prophylactic antibiotics active against Aeromonas are recommended. First-line: ciprofloxacin (oral) or cefotaxime/ceftazidime (IV). First-generation cephalosporins are not effective.
4. Patient Selection & Monitoring
- Screen for immunocompromised status (highest risk group)
- Monitor wound for 48–72 hours post-treatment
- Obtain wound culture for any suspected infection with specific Aeromonas request
- Initiate empiric antibiotics pending sensitivity results
Evidence Summary
GRADE Evidence Level: Low
Observational studies or RCTs with serious limitations
The antimicrobial properties of SGS are documented primarily through in vitro studies, animal experiments, and microbiological characterization. Clinical evidence is observational. One controlled comparison (Seleznev, n=273) demonstrated antimicrobial effect in an otitis population. No randomized controlled trials have specifically evaluated SGS antimicrobial efficacy.
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Andreev PF 1923 | In vivo / animal model | Leeches fed on infected guinea pigs, rats, chickens (n=NR) | Pathogen survival assay in leech intestinal canal | Pathogen viability over time | Typhoid and paratyphoid killed within days-weeks; anthrax attenuated but residue persists; plague bacillus survived 20+ days (transmitted to healthy guinea pig). Pioneering pathogen survival study |
| Petrov EI et al. 1936 | In vitro | Staphylococcus cultures (n=NR) | Extract from leech heads applied to bacterial cultures | Bactericidal activity | Staphylococcus growth inhibited at low concentrations; killed at higher concentrations. Chamberland-filtered extract retained weaker activity. Early in vitro antimicrobial evidence |
| Shpolyansky AA 1944 | Prospective observational | Parametritis patients (n=NR) | Hirudotherapy | Staphylococcal colony counts on agar | Colony numbers decreased 2–3 fold after hirudotherapy. Clinical antimicrobial observation |
| Graf J 1999 | Biochemical / taxonomic characterization | European and Mediterranean medicinal leeches (n=13) | 10 specific biochemical tests on intestinal canal extracts | Symbiont species identification | Predominant culture is A. veronii biovar sobria (not A. hydrophila as assumed). Confirmed by genetic analysis. Pure culture in intestinal canal is remarkable. J Clin Microbiol |
| Indergand S & Graf J 2000 | In vitro / controlled | E. coli, P. aeruginosa, S. aureus in leech intestinal environment (n=NR) | Pathogen introduction into leech intestinal canal with complement analysis | Pathogen survival and complement-mediated killing | E. coli sharply decreased by 42h (complement C5b-9 lysis); Aeromonas resistant due to S-layer protein. P. aeruginosa and S. aureus persisted 162h but proliferation suppressed. Complement-mediated mechanism elucidated |
| Eroglu C et al. 2001 | Microbiological survey | Medicinal leech specimens (surface, oral cavity, intestinal canal) (n=16) | Bacterial isolation and identification from 73 isolates | Flora characterization and antibiotic sensitivity | A. hydrophila (n=25), O. anthropi (n=23), NFGNB (n=12), A. lwoffii (n=3), A. sobria (n=2). 100% sensitivity to ciprofloxacin, cefotaxime, ceftazidime, gentamicin, TMP/SMX. Comprehensive flora + sensitivity data |
| de Chalain TMB 1996 | Meta-analysis / retrospective | Reconstructive surgery patients receiving HT (n=145) | Hirudotherapy for venous congestion | Wound infection rate | Clinical infection rate 7–20% across 37 + 108 cases from multiple surgical centres. Highest risk in daily application for graft salvage. Key infection rate reference |
| Zavalova LL et al. 2000 | Biochemical characterization | Hirudo medicinalis SGS (n=NR) | Recombinant destabilase expression and functional assay | Dual isopeptidase + lysozyme activity | Destabilase exhibits both isopeptidase (thrombolytic) and muramidase (antibacterial) activities in a single 12.3 kDa protein. Primary direct antimicrobial effector in SGS. Biochemistry (Moscow) |
| Seleznev KG et al. 1992 | Non-randomized controlled | Otitis patients (acute external, chronic, tinnitus) (n=273) | SGS microelectrophoresis vs hirudotherapy vs pharmacotherapy | Microbial reduction and microcirculation | SGS microelectrophoresis 25–30% less effective than full HT but from single session. Reduced S. aureus, E. coli, Proteus colony counts on auditory canal skin. SGS-specific antimicrobial clinical data |
Evidence Gaps & Research Priorities
What We Know
- Destabilase-lysozyme is the primary direct antimicrobial in SGS
- Complement-mediated killing operates in the intestinal canal
- The predominant symbiont is A. veronii biovar sobria
- Infection rates: 7–20% in reconstructive surgery
- Fluoroquinolones, 3rd-gen cephalosporins: 100% sensitivity
- 1st-gen cephalosporins: NOT effective
What Remains Unknown
- Quantitative MIC values for destabilase-lysozyme against clinical isolates
- Role of antimicrobial peptides beyond destabilase in SGS
- Optimal prophylaxis duration (pre- vs post-treatment)
- Impact of ESBL and carbapenem-resistant Aeromonas on clinical protocols
- Whether SGS antimicrobial activity persists beyond the acute feeding period
- Comparative infection rates between medicinal leech species
ASH supports the development of standardized antimicrobial susceptibility testing protocols for leech-associated organisms and prospective surveillance studies to monitor resistance trends in clinical Aeromonas isolates.
Key Takeaways
- 1. SGS exerts direct antimicrobial activity through destabilase-lysozyme (cell wall hydrolysis), enhancement of phagocytosis, and complement-mediated bactericidal reactions.
- 2. The predominant leech intestinal symbiont is A. veronii biovar sobria (not A. hydrophila), confirmed by biochemical and genetic analysis (Graf 1999). It resists complement killing via S-layer protein.
- 3. Clinical infection rates with Aeromonas range from 7–20%, primarily in reconstructive surgery and immunocompromised patients.
- 4. Effective antibiotics: ciprofloxacin, 3rd-gen cephalosporins, aminoglycosides (100% sensitivity). First-generation cephalosporins are ineffective.
- 5. Infection risk is minimized by fasted leeches (≥6 months), strict husbandry, prophylactic antibiotics in high-risk patients, and wound culture for any suspected infection.
- 6. The antimicrobial balance reflects an evolutionary interplay between anti-pathogen mechanisms and symbiont-protective adaptations; clinical practice must account for both sides of this duality.